The FDA has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for Opdivo and Yervoy ...

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as a first-line therapy for patients with a ...

Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a ...

Bristol-Myers saw its share prices grow by 3.67 percent on Monday to finish at $57.88 apiece as investors cheered news of the ...

Looking for undervalued stocks? We identified the top undervalued stocks in March 2025. Check out the list here.

The application was based on results from the three-arm Phase 3 CheckMate -8HW study.

Bristol Myers said about 5% to 7% of people with metastatic colorectal cancer have microsatellite instability-high or mismatch-repair-deficient tumors, adding that these patients are less likely to ...

How intelligent technologies are transforming the biopharma industry’Life-changing interventions that have previously been ...

KEYTRUDA monotherapy is the recommended first-line treatment for recurrent or metastatic HNSCC with high PD-L1 expression, ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

TORONTO, ON / ACCESS Newswire / February 24, 2025 / AmeriTrust Financial Technologies Inc. ("AmeriTrust" or the "Company"), a fintech platform targeting automotive finance and specializing in used ...